

February 17, 2024

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	--

Sub: Update on Investment in M/s. Immunoadoptive Cell Therapy Private Limited

Ref:

- 1. Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 dated May 31, 2023**
- 2. Update on payment of Tranche-1 subscription amount to M/s. Immunoadoptive Cell Therapy Private Limited dated July 12, 2023**

Dear Sirs,

This has reference to our disclosures dated May 31, 2023 and July 12, 2023 regarding the signing of definitive agreements to acquire additional stake of 7.24% (on fully diluted basis) in Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs. 80 Crores and update on payment of Tranche-1 subscription amount to ImmunoACT respectively.

In this regard, we wish to update that the Company has paid the subscription amount of Rs. 32,00,75,184/- (Rupees Thirty Two Crores Seventy Five Thousand One Hundred and Eighty Four only) as “Tranche 2 (Final) Subscription Amount”.

The Shareholding of the Company in ImmunoACT is 33.86% (on a fully-diluted basis).

This is for your information and record.

Yours faithfully,
For Laurus Labs Limited

G. Venkateswar Reddy
Company Secretary &
Compliance Officer